Ensysce reports Q4 net loss $3.6M, cash $3.5M; signs PF614 commercial launch partner

Ensysce Biosciences, Inc.

Cash $3.5M at Dec 2024 vs $4.2M Sept 2024 and $1.1M Dec 2023; 2024 net loss $8.0M vs $10.6M in 2023.
Entered strategic partnership with specialty manufacturer for commercial launch of PF614 and PF614-MPAR.
PF614-MPAR-102 interim data show overdose protection at 100 mg dose; study continues at higher doses.
FDA feedback on PF614 phase 3 design received; enrollment expected Q2 2025; NDA submission targeted for 2026.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-25-009695
form_type: 8-K
ticker: ENSC
cik: 0001716947
company_name: Ensysce Biosciences, Inc.
filed_at: 2025-03-10T23:59:59+00:00
discovered_at: 2026-05-14T18:03:04.570758+00:00
generated_at: 2026-05-25T01:48:30.177841+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-25-009695
json_url: https://secwatch.observer/filing/0001493152-25-009695.json
markdown_url: https://secwatch.observer/filing/0001493152-25-009695.md
text_url: https://secwatch.observer/filing/0001493152-25-009695.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315225009695/0001493152-25-009695-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315225009695/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-25-009695

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.